SynthesisBMC psychiatry2025
Prevalence of metabolic syndrome in Chinese patients with schizophrenia: a systematic review and meta-analysis.
Synthesis in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Concomitant pathologies and their impact on schizophrenia: a narrative overview of current evidence.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- From Catering to Clinical Care: An Expert Survey on Designing the Inpatient Psychiatric Meal Concept.Nutrients · 2026Article
- Cross-population validation of European GWAS loci for metabolic syndrome in Chinese schizophrenia.BMC psychiatry · 2026Article
- Prevalence and risk profiles of metabolic abnormalities (PRIMA): a large-scale, multicenter cross-sectional study among inpatients with schizophrenia in China.BMC psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPremature mortality in schizophrenia is associated with comorbidity with metabolic syndrome (MetS). In China, existing studies have reported inconsistent findings regarding the prevalence of MetS among patients with schizophrenia, with limited nationally representative epidemiological data. This meta-analysis aimed to (1) determine the pooled prevalence of MetS in a Chinese population with schizophrenia and (2) systematically evaluate subgroup disparities across demographic, clinical, and treatment-related variables.
methodsThe PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform, VIP Journal Integration Platform, and China Biology Medicine databases were searched for cross-sectional studies on the prevalence of MetS in China, without any search restrictions. Subgroup analyses were performed according to first-episode status, sex, age group, marital status, educational level, illness duration, body mass index (BMI), smoking history, alcohol-use history, family history of schizophrenia/diabetes/hypertension, and medication history.
resultsWe included 73 studies with a total sample size of 34,655 patients with schizophrenia, including 10,944 patients with MetS. The pooled analysis revealed a combined prevalence of schizophrenia and MetS in China of 31.4% (95% confidence interval: 28.8–34.0). There were significantly elevated risks of MetS observed in older adults (≥50 years), prolonged hospitalization, longer illness duration ( > 10 years), higher BMI, family history of diabetes, and smokers. No significant differences in the prevalence of MetS were observed between groups according to sex, marital status, educational attainment, alcohol consumption, family history of schizophrenia or hypertension, use of first- or second-generation agents, and monotherapy or combination therapy with antipsychotics.
conclusionsThis meta-analysis revealed a pooled prevalence of MetS of 31.4% among Chinese patients with schizophrenia. Given the heightened risk of cardiovascular morbidity and mortality associated with MetS in patients with schizophrenia, particularly in the subgroups of older adults, prolonged hospitalization, longer illness duration, higher BMI, family history of diabetes, and smokers, our study indicates the following interventions: (1) universal screening: routine metabolic monitoring integrated into psychiatric care protocols, (2) precision prevention: targeted interventions for high-risk subgroups (e.g., BMI management in obese patients and smoking cessation programs), (3) and nutritional empowerment: structured dietary education to improve metabolic health and potentially augment cognitive functioning. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.